Aevice Health vs Beam Therapeutics

Side-by-side comparison of AI visibility scores, market position, and capabilities

AI visibility is closely matched (37 vs 38)
Aevice Health logo

Aevice Health

EmergingBioTech

Digital Health

Aevice Health raised $30M Series B in 2025 for its AI-powered wearable respiratory monitor that continuously tracks wheezing, coughing, and breathing abnormalities in asthma and COPD patients.

AI VisibilityBeta
Overall Score
D37
Category Rank
#1 of 1
AI Consensus
65%
Trend
up
Per Platform
ChatGPT
43
Perplexity
46
Gemini
43

About

Aevice Health develops wearable respiratory monitoring technology that uses AI to analyze breath sounds captured continuously from a chest-worn device. The AeviceMD system detects wheezing, coughing, and abnormal breathing patterns in real time, enabling early warning of asthma attacks and COPD exacerbations before they require emergency care. The device transmits data to a smartphone app and clinical dashboard for remote monitoring by pulmonologists.

Full profile
Beam Therapeutics logo

Beam Therapeutics

GrowthBiotechnology

Base Editing Gene Therapy

Beam Therapeutics develops precision genetic medicines using base editing technology that makes single-letter DNA changes without cutting the double helix.

AI VisibilityBeta
Overall Score
D38
Category Rank
#1 of 1
AI Consensus
64%
Trend
up
Per Platform
ChatGPT
44
Perplexity
34
Gemini
29

About

Beam Therapeutics is a genetic medicines company founded in 2017 by base editing pioneers David Liu, J. Keith Joung, and Feng Zhang, having raised over $600M and gone public on Nasdaq. The company is built around base editing, a technology that makes precise single nucleotide changes in DNA without creating double-strand breaks, reducing the risk of unintended insertions or deletions compared to traditional CRISPR. Beam is developing a portfolio of base editing medicines targeting blood disorders, liver diseases, and immuno-oncology, including sickle cell disease, beta-thalassemia, and various cancers. The company also employs prime editing, a newer and even more precise gene editing modality for more complex genetic changes. Beam's pipeline includes both in vivo therapies delivered directly into the body and ex vivo cell therapy approaches where patient cells are edited outside the body and reinfused. As a clinical-stage company, Beam has programs in IND-enabling and Phase 1 trials and represents one of the most advanced next-generation gene editing platforms in development.

Full profile

AI Visibility Head-to-Head

37
Overall Score
38
#1
Category Rank
#1
65
AI Consensus
64
up
Trend
up
43
ChatGPT
44
46
Perplexity
34
43
Gemini
29
32
Claude
30
36
Grok
34

Key Details

Category
Digital Health
Base Editing Gene Therapy
Tier
Emerging
Growth
Entity Type
brand
brand

Capabilities & Ecosystem

Capabilities

Only Aevice Health
Digital Health
Only Beam Therapeutics
Base Editing Gene Therapy

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.